CRSP,NKTX Stock Price and Quote

Peers: EDIT NTLA BEAM SGMO VRTX GILD BLUE ALLO CLLS ADPT

| Held by: ARKK IWM ARKG XBI VXF IWN IBB VTWO SCHA SCHM

Index	RUT	P/E	-	EPS (ttm)	-6.51	Insider Own	3.79%	Shs Outstand	95.89M	Perf Week	8.88%
Market Cap	5.06B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-6.01%	Shs Float	89.08M	Perf Month	-6.71%
Enterprise Value	3.28B	PEG	-	EPS next Q	-1.21	Inst Own	67.55%	Short Float	24.57%	Perf Quarter	1.69%
Income	-581.60M	P/S	1440.90	EPS this Y	25.69%	Inst Trans	3.35%	Short Ratio	11.58	Perf Half Y	-9.78%
Sales	3.51M	P/B	2.65	EPS next Y	21.49%	ROA	-25.81%	Short Interest	21.89M	Perf YTD	1.20%
Book/sh	20.04	P/C	2.55	EPS next 5Y	28.81%	ROE	-30.18%	52W High	78.48 -32.38%	Perf Year	22.03%
Cash/sh	20.81	P/FCF	-	EPS past 3/5Y	8.21% -4.10%	ROIC	-27.56%	52W Low	30.04 76.66%	Perf 3Y	3.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	43.09% 37.31%	Gross Margin	-6534.67%	Volatility	5.53% 6.00%	Perf 5Y	-67.05%
Dividend TTM	-	EV/Sales	934.72	EPS Y/Y TTM	-49.45%	Oper. Margin	-16191.40%	ATR (14)	3.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.32	Sales Y/Y TTM	-90.59%	Profit Margin	-16569.77%	RSI (14)	51.98	Recom	1.90
Dividend Gr. 3/5Y	- -	Current Ratio	13.32	EPS Q/Q	-214.02%	SMA20	2.05%	Beta	1.75	Target Price	81.17
Payout	-	Debt/Eq	0.11	Sales Q/Q	-97.58%	SMA50	-2.42%	Rel Volume	1.30	Prev Close	48.93
Employees	393	LT Debt/Eq	0.10	Earnings	Feb 12 AMC	SMA200	-1.52%	Avg Volume	1.89M	Price	53.07
IPO	Oct 19, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.81% -81.69%	Trades		Volume	2,463,922	Change	8.46%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	JP Morgan	Overweight	$70
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60

Show Previous Ratings

Feb-14-26 09:06AM	Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI (TipRanks)
09:05AM	Crispr Therapeutics price target raised to $82 from $80 at Needham (TipRanks)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga) +8.46%
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
08:00AM	Loading…
08:00AM	Vertexs CRISPR therapy rebounds in latest earnings (BioPharma Dive)
Feb-12-26 06:00PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:30PM	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
Feb-09-26 10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-06-26 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks) +6.23%
Feb-05-26 07:28PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) -8.55%
10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
07:19AM	Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline (Insider Monkey)
06:52PM	Loading…
Feb-04-26 06:52PM	Blue Bird Q1 Earnings Call Highlights (MarketBeat)
Feb-03-26 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-02-26 05:50PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jan-30-26 08:07AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) -6.35%
07:06AM	Cathie Wood Doubles Down on Joby Aviation After Stock Crashes 17% (GuruFocus.com)
Jan-29-26 12:48PM	Forget AI Stocks: This Biotech Could Cure What AI Can't Touch (Motley Fool)
07:18AM	BofA is Bullish on CRISPR Therapeutics AG (CRSP) (Insider Monkey)
Jan-27-26 04:33AM	Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops (Benzinga)
Jan-26-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-23-26 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks) -8.70%
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga) +11.11%
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-18-26 12:00PM	3 Seasonal Stocks to Buy Immediately (InvestorPlace)
05:50PM	Loading…
Jan-15-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-13-26 09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks)
Jan-12-26 12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
09:30AM	CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
08:36AM	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones (GlobeNewswire)
Jan-09-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.51%
Jan-05-26 06:00PM	CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why (Zacks)
08:30AM	CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
Dec-30-25 11:49PM	Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP) (Insider Monkey)
05:50PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
07:40AM	Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-28-25 10:05AM	CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update (Insider Monkey)
Dec-27-25 01:15PM	Cathie Wood drops $1.3 million on healthcare stock (TheStreet)
Dec-26-25 10:56AM	Cathie Wood Doubles Down on Self-Driving and Gene-Editing Stocks Ahead of 2026 (GuruFocus.com)
06:20AM	These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? (Motley Fool)
Dec-24-25 04:35AM	Is CRISPR Therapeutics Stock Yesterday's News? (Motley Fool)
Dec-23-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
02:38PM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
Dec-22-25 08:30AM	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies (GlobeNewswire)
Dec-19-25 09:00AM	Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? (Zacks)
07:05AM	Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? (Motley Fool)
Dec-18-25 12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Dec-17-25 05:50PM	CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Dec-16-25 10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Dec-15-25 11:30AM	12 Days of Investing: My Top 12 Stocks to Buy Before 2026 (Motley Fool)
Dec-12-25 01:05PM	2 Healthcare Stocks to Buy Ahead of the New Year (Motley Fool)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-08-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-07-25 09:45AM	2 Stocks That Could Soar by 52% and 282%, According to Wall Street (Motley Fool)
Dec-04-25 11:22PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Dec-03-25 09:01AM	Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks) +8.55%
Dec-01-25 05:28AM	What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors (Insider Monkey)
Nov-30-25 04:10AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% (Motley Fool)
Nov-29-25 01:23PM	The Best Stocks to Buy With $1,000 Right Now (Motley Fool)
01:08PM	Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown (Insider Monkey)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-25-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:39AM	Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance (Insider Monkey)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
04:31AM	3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential (Motley Fool)
Nov-20-25 06:48PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Nov-19-25 03:42PM	This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? (Barchart) -5.12%
06:05AM	Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Nov-18-25 11:05AM	4 Struggling Stocks With "Harmless" Pullbacks (Schaeffer's Research)
08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform (Insider Monkey)
Nov-17-25 06:53AM	1 Underrated Stock That Could Soar by 58%, According to Wall Street (Motley Fool) +5.31%
Nov-14-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga) -5.47%
07:02AM	Cathie Wood doubles down on Alibaba: ARK Invest snaps up $25M in Chinese tech stocks (GuruFocus.com)
Nov-11-25 05:55PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
Nov-10-25 04:58PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com)
09:10AM	CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
09:56AM	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering (GlobeNewswire)
Nov-07-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Nov-05-25 11:35AM	VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? (Zacks)
Nov-04-25 04:13PM	Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat (Investor's Business Daily) -8.97%

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Naimish	Chief Medical Officer	Apr 03 '25	Buy	32.96	1,508	49,704	1,508	Jan 27 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Option Exercise	45.15	34,972	1,578,986	41,739	Jan 26 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Sale	60.19	34,972	2,104,965	6,767	Jan 26 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Jan 22 '26	Sale	60.23	60,000	3,613,800	134,201	Jan 22 05:55 PM
Kulkarni Samarth	Chief Executive Officer	Jan 20 '26	Sale	51.75	30,000	1,552,498	194,201	Jan 22 05:55 PM
Samarth Kulkarni	Officer	Jan 22 '26	Proposed Sale	60.81	60,000	3,648,600		Jan 22 05:15 PM
RAJU PRASAD	Officer	Jan 22 '26	Proposed Sale	60.19	34,972	2,105,070		Jan 22 04:03 PM
Samarth Kulkarni	Officer	Jan 20 '26	Proposed Sale	52.61	30,000	1,578,300		Jan 20 05:11 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Option Exercise	44.97	29,700	1,335,630	36,467	Jan 08 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Sale	60.16	29,700	1,786,636	6,767	Jan 08 05:35 PM
RAJU PRASAD	Officer	Jan 06 '26	Proposed Sale	60.16	29,700	1,786,636		Jan 06 05:11 PM
Prasad Raju	Chief Financial Officer	Dec 22 '25	Sale	55.95	10,000	559,549	6,767	Dec 23 05:33 PM
RAJU PRASAD	Officer	Dec 22 '25	Proposed Sale	55.95	10,000	559,548		Dec 22 04:20 PM
Kulkarni Samarth	Chief Executive Officer	Oct 17 '25	Sale	67.91	50,895	3,456,279	254,201	Oct 20 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '25	Sale	66.60	4,242	282,517	205,096	Oct 15 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '25	Sale	66.60	1,076	71,662	83,402	Oct 15 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Aug 18 '25	Sale	58.15	13,081	760,660	207,004	Aug 19 04:30 PM
Treco Douglas A	Director	Aug 06 '25	Buy	57.03	20,000	1,140,600	22,000	Aug 08 04:06 PM
George Simeon	Director	Jul 16 '25	Buy	52.03	989,812	51,499,918	1,730,179	Jul 17 05:19 PM
Patel Naimish	Chief Medical Officer	May 29 '25	Sale	35.94	3,932	141,316	6,068	May 30 05:00 PM
Kulkarni Samarth	Chief Executive Officer	Mar 21 '25	Sale	41.23	10,031	413,578	195,085	Mar 24 05:35 PM
Bruno Julianne	Chief Operating Officer	Mar 21 '25	Sale	41.23	1,714	70,668	10,544	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 21 '25	Sale	41.23	2,197	90,582	16,767	Mar 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 21 '25	Sale	41.23	3,185	131,318	81,729	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 17 '25	Sale	41.80	3,762	157,252	12,714	Mar 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '25	Sale	42.42	9,973	423,055	180,890	Mar 12 07:05 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '25	Sale	43.32	4,462	193,294	185,428	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '25	Sale	42.42	2,850	120,897	77,530	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '25	Sale	43.32	1,116	48,345	78,664	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 11 '25	Sale	42.42	1,198	50,819	8,263	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 12 '25	Sale	43.32	190	8,231	8,508	Mar 12 07:05 PM
Greene John	Director	Feb 26 '25	Buy	44.85	7,000	313,948	7,000	Feb 28 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	55.20	18,360	1,013,564	171,613	Feb 21 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 18 '25	Sale	55.05	11,640	640,782	196,901	Feb 19 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	52.80	6,928	365,798	189,973	Feb 19 05:35 PM
Bruno Julianne	Chief Operating Officer	Feb 19 '25	Sale	52.80	333	17,582	7,062	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 18 '25	Sale	53.85	9,595	516,691	73,002	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '25	Sale	52.80	1,947	102,802	74,880	Feb 19 05:35 PM
Samarth Kulkarni	Officer	Feb 18 '25	Proposed Sale	52.22	45,000	2,349,900		Feb 18 05:35 PM

CRSP

CRISPR Therapeutics AG

NKTX

Nkarta Inc

Upgrade your FINVIZ experience